Lactobacillus paracasei Vesicles for Metabolic Disorder Treatment

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current treatments for obesity and insulin resistance do not effectively address metabolic disorders caused by high-fat diets, particularly in animal models, and there is a lack of therapeutic use of Lactobacillus-derived vesicles for these conditions.

Innovation Solution

A pharmaceutical and food composition utilizing isolated vesicles from Lactobacillus paracasei bacteria, which are administered to inhibit obesity and insulin resistance by reducing body weight, food intake, and improving metabolic disorders through AMPK signaling activation in myocytes.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If Lactobacillus-derived vesicles are used to treat obesity and insulin resistance, then metabolic disorders are improved, but the therapeutic mechanism and effectiveness in animal models need further validation

Engineering Contradiction:
Improvetherapeutic effectivenessVSAvoidapplication scope
Core Design Contradiction:
ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent converts the harmful effect of high-fat diet-induced metabolic disorders into a beneficial therapeutic opportunity by using Lactobacillus vesicles to treat obesity and insulin resistance. The vesicles are derived from bacterial components that normally could be considered harmful (bacterial cell wall components like peptidoglycan and lipoteichoic acid) but are repurposed to activate AMPK signaling and improve metabolic health.

Inventive Principle:
Principle #22Blessing in disguise (Convert harm into benefit)

2Weight of moving object

If isolated vesicles from Lactobacillus paracasei are administered, then body weight and food intake are reduced, but the mechanism of action requires further elucidation

Engineering Contradiction:
Improvebody weightVSAvoidmechanism detection
Core Design Contradiction:
Weight of moving objectVSDifficulty of detecting and measuring

Solution Approach 1:

The patent employs feedback mechanisms by measuring various parameters (body weight, food intake, metabolic markers) to evaluate the therapeutic effect of Lactobacillus vesicles. The AMPK signaling pathway activation serves as a molecular feedback indicator that confirms the mechanism of action, allowing researchers to correlate vesicle administration with specific biochemical changes.

Inventive Principle:
Principle #23Feedback

3Adaptability or versatility

If vesicles are secreted by Lactobacillus bacteria, then intracellular exchange of proteins, lipids or genes is enabled, but the therapeutic application for metabolic diseases is not yet established

Engineering Contradiction:
Improvefunctional capabilityVSAvoidtherapeutic reliability
Core Design Contradiction:
Adaptability or versatilityVSReliability

Solution Approach 1:

The patent demonstrates universality by showing that Lactobacillus vesicles, which naturally function in intracellular exchange of proteins, lipids, and genes, can also serve multiple therapeutic functions in treating metabolic diseases. The same vesicles that enable bacterial communication are shown to activate AMPK signaling, reduce body weight, and improve insulin sensitivity across different metabolic disorder models.

Inventive Principle:
Principle #6Universality (Multi-functionality)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The vesicles derived from Lactobacillus paracasei effectively reduce body weight and metabolic disorders by activating AMPK signaling, demonstrating potential in treating obesity, metabolic syndrome, and related conditions in animal models.

Implementation Method 1

improving metabolic disorders through AMPK signaling activation in myocytes

Methodology Applied
Scientific EffectAMPK signaling activation:

Data Source

PatentEP3960192B1Composition comprising lactobacillus bacterium-derived vesicle for preventing or treating obesity or insulin resistance
Publication Date: 2024.08.07 MD HEALTHCARE INC
  • EP3960192B1 patent drawingFigure 1
  • EP3960192B1 patent drawingFigure 2A~2C
  • EP3960192B1 patent drawingFigure 3

AI summary

The present invention relates to a composition for preventing or treating a metabolic disease or muscle disease, which comprises vesicles derived from bacteria of the genus Lactobacillus. The inventors confirmed that, when vesicles derived from bacteria of the genus Lactobacillus were administered into an animal model with a metabolic disease caused by a high fat, the vesicles effectively inhibit metabolic diseases caused by a high fat diet, and increase homeostasis to metabolic stress by activating AMPK signaling in myocytes, and therefore, the vesicles derived from bacteria of the genus Lactobacillus according to the present invention can be effectively used in development of pharmaceuticals or health functional foods for preventing, improving symptoms or treating metabolic diseases such as obesity and muscle diseases.